title: Endocrine cells in intraductal papillary-mucinous neoplasms of the pancreas. A histochemical and immunohistochemical study.
abstract: The endocrine cells in intraductal papillary-mucinous neoplasms (IPN) of the pancreas have rarely been investigated. In the normal pancreatic ducts of normal pancreases (n = 5) there were a few endocrine cells: argyrophil in 5 (100%), chromogranin A in (100%), pancreatic polypeptide (PP) in 3 (60%), and insulin in 7 (20%). These endocrine cells were scattered, and located in the basal portions of pancreatic ducts. In IPN of the pancreas (n = 9), there were many endocrine cells: argyrophil in 7 (78%), argentaffin in 8 (89%), chromogranin A in 8 (89%), PP in 7 (78%), serotonin in 7 (78%), insulin in 4 (44%), and gastrin in 5 (56%). In invasive ductal adenocarcinoma of the pancreas (n = 6), many endocrine cells were also detected: argyrophil cells in (67%), chromogranin A in 3 (50%), insulin in 3 (50%), glucagon in 4 (67%), and somatostatin in 3 (50%). In positive cases, endocrine cells were situated under or among the neoplastic cells and the proportion of endocrine cells in IPN was less than 5% of the total neoplastic cell population. These data show that normal pancreatic ducts contain endocrine cells and that IPN frequently contain argyrophil, argentaffin, chromogranin A, and hormone-containing endocrine cells. These data also suggest that endocrine differentiation occurs during neoplastic transformation and progression of IPN of the pancreas.
authors.affiliation: Second Department of Pathology, Tottori University Faculty of Medicine, Yonago, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Terada
authors.forename: T
authors.initials: T
authors.lastname: Ohta
authors.forename: Y
authors.initials: Y
authors.lastname: Kitamura
authors.forename: K
authors.initials: K
authors.lastname: Ashida
authors.forename: Y
authors.initials: Y
authors.lastname: Matsunaga
authors.forename: M
authors.initials: M
authors.lastname: Kato
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000737:chemistry / Q000473:pathology*; D000236:Adenoma / Q000737:chemistry / Q000473:pathology*; D000368:Aged; D000369:Aged, 80 and over; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry / Q000473:pathology*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000737:chemistry / Q000473:pathology*; D053379:Chromogranin A; D002864:Chromogranins / Q000032:analysis / Q000276:immunology; D004759:Enterochromaffin Cells / Q000737:chemistry / Q000473:pathology; D005260:Female; D005755:Gastrins / Q000032:analysis / Q000276:immunology; D005934:Glucagon / Q000032:analysis / Q000276:immunology; D006651:Histocytochemistry; D006801:Humans; D007150:Immunohistochemistry; D007328:Insulin / Q000032:analysis / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000737:chemistry / Q000473:pathology*; D010191:Pancreatic Polypeptide / Q000032:analysis / Q000276:immunology; D012701:Serotonin / Q000032:analysis / Q000276:immunology; D014660:Vasoactive Intestinal Peptide / Q000032:analysis / Q000276:immunology
chemical_list: D053379:Chromogranin A; D002864:Chromogranins; D005755:Gastrins; D007328:Insulin; D012701:Serotonin; D014660:Vasoactive Intestinal Peptide; D010191:Pancreatic Polypeptide; D005934:Glucagon